Calidi Biotherapeutics Q3 2026 Results: Net Loss of $3.65M, Loss Narrows
Calidi Biotherapeutics reported a net loss of $11.9 million for the nine months ended September 30, 2026, compared to a $16.0 million loss in the prior year period. The company maintained a cash balance of $3.9 million as of September 30, 2026, and completed a 1-for-16 reverse stock split in July 2026 to adjust its capital structure.
- Key figure
- Net loss $3.65M